Detailed narrative
Bronchiectasis Market Opportunity and Awareness Campaigns
Electromed continues to target the underserved bronchiectasis market, where approximately 1 million patients are diagnosed in the US, but only about 16% currently benefit from high-frequency chest wall oscillation (HFCWO) therapy. This leaves 800,000 diagnosed patients and over 4 million potentially undiagnosed individuals. The company's 'Triple Down on Bronchiectasis' campaign, initiated last year, focuses on a 3-part treatment approach: clear airways first with SmartVest, treat infection with antibiotics, and reduce inflammation. This year, they expanded with 'Treat Smart from the Start' to help clinicians identify patients whose current airway clearance therapy is insufficient.
Payer Coverage Expansion and E-prescribe Adoption
Expanding payer coverage remains a core strategy, with Electromed ending the year with 87% of covered lives in the US under contract. The market access team executed 40 new payer contracts and expanded the network by over 6 million covered lives. The Smart Order e-prescribe solution is gaining traction, handling more than 45% of orders in Q4 and shipping them 5 days faster than faxed orders. This positions the company well ahead of CMS's new administrative simplification rule, which mandates phasing📎 out faxes by May 2028.
Sales Force Expansion and Productivity
The company ended Q4 with 64 direct sales representatives, an increase of 6 reps from Q3, reflecting hiring ahead of planned territory expansions in fiscal 2027. The goal for FY27 is to have 67 territories filled, including 2 hospital account liaisons. In FY26, the annualized home care revenue per weighted average direct sales representative was $1,145,000, exceeding the target range. For FY27, the target range has been adjusted to $1,050,000 to $1,150,000 to account for new rep ramp-up.
R&D Focus and M&A Strategy
Electromed's R&D investment, though on a small base, is bifurcated between sustaining engineering for existing technology upgrades and innovation. Key innovation areas include connectivity solutions and expanding the vest line, particularly for smaller sizes. The company is also actively looking for inorganic growth opportunities, seeking acquisitions that could add complementary products to their sales reps' bags or leverage their strong reimbursement team and contracting engine in the home care space.
Leadership Transition and Company Culture
CEO Jim Cunniff announced his decision to retire in April 2027, following a thoughtful succession planning process led by the Board. He expressed confidence in the company's future and its talented leadership team. Electromed was recognized as the eighth fastest-growing public company in Minnesota and a top workplace, with 45% of new hires in FY26 coming through employee referrals, highlighting a strong employee engagement and culture.